Several biotechnology companies have recently earned ratings from analysts as of April 28, 2026. These ratings are often driven by positive clinical trial progress, strategic acquisitions, or analyst upgrades following strong performance. Latest Analyst "Strong Buy" Upgrades
These stocks have received specific "Strong Buy" ratings or upgrades from major financial institutions in late April 2026: strong buy biotech stocks
: Upgraded to Strong Buy by Truist Financial and BTIG Research . strong buy biotech stocks
: Rating increased to Strong Buy at Truist Financial. strong buy biotech stocks